4,447 reports of this reaction
2.0% of all VEDOLIZUMAB reports
#10 most reported adverse reaction
ARTHRALGIA is the #10 most commonly reported adverse reaction for VEDOLIZUMAB, manufactured by Takeda Pharmaceuticals America, Inc.. There are 4,447 FDA adverse event reports linking VEDOLIZUMAB to ARTHRALGIA. This represents approximately 2.0% of all 224,197 adverse event reports for this drug.
VEDOLIZUMAB has an overall safety score of 88 out of 100. Patients taking VEDOLIZUMAB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for VEDOLIZUMAB, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for VEDOLIZUMAB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 4,447 FDA reports for VEDOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.0% of all adverse event reports for VEDOLIZUMAB, making it a notable side effect.
If you experience arthralgia while taking VEDOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.